| 1 |
32259780 | Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission. | 2020 Apr |
1 |
| 2 |
32273207 | Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO. | 2020 Jun |
2 |
| 3 |
32436244 | A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease? | 2020 Sep |
1 |
| 4 |
33117463 | Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial. | 2020 Oct |
1 |
| 5 |
33283132 | Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. | 2020 |
1 |
| 6 |
30389744 | Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer. | 2019 Feb |
1 |
| 7 |
30460489 | Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project. | 2019 Feb |
1 |
| 8 |
30952749 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. | 2019 Apr |
1 |
| 9 |
30979740 | Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. | 2019 Jul 1 |
1 |
| 10 |
31477168 | A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). | 2019 Sep 2 |
1 |
| 11 |
29327055 | Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. | 2018 Mar 1 |
2 |
| 12 |
29328489 | Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptorĀ 2-positive gastric cancer. | 2018 Mar |
1 |
| 13 |
30150888 | The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. | 2018 |
2 |
| 14 |
27831502 | Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. | 2017 Mar 1 |
1 |
| 15 |
28256066 | Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. | 2017 May |
1 |
| 16 |
28413662 | Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer. | 2017 Apr |
1 |
| 17 |
28701571 | Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. | 2017 Nov |
1 |
| 18 |
29285378 | Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer. | 2017 Dec |
1 |
| 19 |
27171333 | [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. | 2016 May |
1 |
| 20 |
27919976 | Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer. | 2016 Dec |
1 |
| 21 |
27920708 | Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report. | 2016 Sep-Dec |
1 |
| 22 |
25065563 | High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. | 2015 Feb |
1 |
| 23 |
25579459 | Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. | 2015 Jun |
1 |
| 24 |
25678799 | Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases. | 2015 |
3 |
| 25 |
25931813 | Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. | 2015 |
1 |
| 26 |
26029934 | Treatment of metastatic breast cancer with š¯‘›š¯‘ˇš¯‘¸-paclitaxel in the community practice setting: a US Oncology survey. | 2015 May |
3 |
| 27 |
26673577 | Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. | 2015 Dec 16 |
1 |
| 28 |
21359953 | Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. | 2012 Apr |
1 |
| 29 |
21887460 | Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. | 2011 Dec |
2 |
| 30 |
20585851 | Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. | 2010 Sep |
1 |
| 31 |
18766004 | Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. | 2008 Oct |
3 |